Dennis Carney

4.4k total citations · 2 hit papers
51 papers, 3.4k citations indexed

About

Dennis Carney is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Dennis Carney has authored 51 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Genetics, 25 papers in Pathology and Forensic Medicine and 15 papers in Hematology. Recurrent topics in Dennis Carney's work include Chronic Lymphocytic Leukemia Research (33 papers), Lymphoma Diagnosis and Treatment (25 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Dennis Carney is often cited by papers focused on Chronic Lymphocytic Leukemia Research (33 papers), Lymphoma Diagnosis and Treatment (25 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Dennis Carney collaborates with scholars based in Australia, United States and Italy. Dennis Carney's co-authors include Peng Huang, Hélène Pelicano, John F. Seymour, Andrew W. Roberts, Sari H. Enschede, David Westerman, David C.S. Huang, Andrew Krivoshik, Thomas J. Kipps and Hao Xiong and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Dennis Carney

47 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ROS stress in cancer cells and therapeutic implications

2004 1.7k citations Hélène Pelicano, Dennis Carney et al. Drug Resistance Updates profile →
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

2011 632 citations Andrew W. Roberts, John F. Seymour et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dennis Carney Australia	20	1.7k	703	675	590	451	51	3.4k
Yunfeng Cheng China	32	1.3k 0.8×	335 0.5×	184 0.3×	498 0.8×	698 1.5×	135	4.0k
Timothy Madden United States	37	2.1k 1.3×	463 0.7×	369 0.5×	1.6k 2.8×	1.2k 2.7×	108	4.8k
Li Jia China	35	2.3k 1.4×	273 0.4×	250 0.4×	905 1.5×	256 0.6×	118	4.1k
Cody J. Peer United States	33	1.8k 1.1×	450 0.6×	209 0.3×	1.5k 2.6×	172 0.4×	156	4.0k
Ke Lin United Kingdom	27	927 0.6×	588 0.8×	868 1.3×	476 0.8×	210 0.5×	72	2.4k
Raymond J. Hohl United States	40	2.3k 1.4×	366 0.5×	310 0.5×	1.5k 2.6×	616 1.4×	138	4.9k
Christopher L. Morton United States	45	3.2k 1.9×	406 0.6×	306 0.5×	1.5k 2.6×	204 0.5×	128	5.6k
Patric J. Jansson Australia	42	2.6k 1.6×	438 0.6×	217 0.3×	2.4k 4.0×	405 0.9×	85	5.5k
Žaklina Kovačević Australia	43	3.2k 1.9×	818 1.2×	231 0.3×	1.8k 3.1×	423 0.9×	89	5.6k
Lingyu Zeng China	27	1.1k 0.7×	127 0.2×	276 0.4×	533 0.9×	698 1.5×	219	3.2k

Countries citing papers authored by Dennis Carney

Since Specialization

Citations

This map shows the geographic impact of Dennis Carney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dennis Carney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dennis Carney more than expected).

Fields of papers citing papers by Dennis Carney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dennis Carney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dennis Carney. The network helps show where Dennis Carney may publish in the future.

Co-authorship network of co-authors of Dennis Carney

This figure shows the co-authorship network connecting the top 25 collaborators of Dennis Carney. A scholar is included among the top collaborators of Dennis Carney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dennis Carney. Dennis Carney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wierda, William G., Ryan Jacobs, Paul M. Barr, et al.. (2024). CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study. Clinical Lymphoma Myeloma & Leukemia. 24. S342–S342.

Wierda, William G., Ryan Jacobs, Paul M. Barr, et al.. (2024). Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study. Clinical Lymphoma Myeloma & Leukemia. 24. S179–S179.

Lew, Thomas E., Mary Ann Anderson, Constantine S. Tam, et al.. (2018). Long Term Outcomes of Venetoclax Therapy for Complex Karyotype Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 132(Supplement 1). 4431–4431. 1 indexed citations

Cheah, Chan Y., Michael S. Hofman, John F. Seymour, et al.. (2014). The utility and limitations of¹⁸F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. Leukemia & lymphoma. 56(1). 49–56. 14 indexed citations

Cheah, Chan Y., Kirsten Herbert, Glen Kennedy, et al.. (2014). A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. British Journal of Cancer. 111(6). 1072–1079. 89 indexed citations

Cheah, Chan Y., Michael S. Hofman, Michael Dickinson, et al.. (2013). Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. British Journal of Cancer. 109(2). 312–317. 50 indexed citations

Roberts, Andrew W., John F. Seymour, Jennifer R. Brown, et al.. (2011). Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. Journal of Clinical Oncology. 30(5). 488–496. 632 indexed citations breakdown →

Mikeska, Thomas, Chelsee Hewitt, Dennis Carney, et al.. (2011). 1.30 Caspase 10 is Down-Regulated in Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 11. S159–S159. 1 indexed citations

Carney, Dennis, David Westerman, Constantine S. Tam, et al.. (2010). Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia. 24(12). 2056–2062. 68 indexed citations

10.

Peinert, Stefan, Margaret F. Moloney, H. Miles Prince, et al.. (2009). RAPID INFUSION OF RITUXIMAB IS WELL TOLERATED AND ENABLES MORE EFFICIENT USE OF HAEMATOLOGY DAY WARD RESOURCES. 94. 2 indexed citations

11.

Gill, Saar, Dennis Carney, David Ritchie, et al.. (2009). The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Annals of Oncology. 21(2). 331–334. 32 indexed citations

12.

Gill, Saar, Kirsten Herbert, H. Miles Prince, et al.. (2009). Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. British Journal of Haematology. 147(1). 83–88. 40 indexed citations

13.

Carney, Dennis, et al.. (2008). Negative selection of chronic lymphocytic leukaemia cells using a bifunctional rosette-based antibody cocktail. BMC Biotechnology. 8(1). 6–6. 5 indexed citations

14.

Herbert, Kirsten, Susan Morgan, H. Miles Prince, et al.. (2008). Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator. Leukemia. 23(2). 305–312. 15 indexed citations

15.

Tam, Constantine S., Max Wolf, H. Miles Prince, et al.. (2006). Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non‐hodgkin lymphoma. Cancer. 106(11). 2412–2420. 75 indexed citations

16.

Zhou, Yan, Celia Garcı́a-Prieto, Dennis Carney, et al.. (2005). OSW-1: a Natural Compound With Potent Anticancer Activity and a Novel Mechanism of Action. JNCI Journal of the National Cancer Institute. 97(23). 1781–1785. 84 indexed citations

17.

Carney, Dennis & William G. Wierda. (2005). Genetics and molecular biology of chronic lymphocytic leukemia. Current Treatment Options in Oncology. 6(3). 215–225. 13 indexed citations

18.

Yin, C. Cameron, Pei Lin, Dennis Carney, et al.. (2005). Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Associated With IgM Paraprotein: A Clinicopathologic Study of 26 Cases. American Journal of Clinical Pathology. 123(4). 594–602. 33 indexed citations

19.

Pelicano, Hélène, Dennis Carney, & Peng Huang. (2004). ROS stress in cancer cells and therapeutic implications. Drug Resistance Updates. 7(2). 97–110. 1675 indexed citations breakdown →

20.

Moore, Vicky, Dennis Carney, Susan E. Jasper, et al.. (2000). Performing an Echocardiographic Examination with a Contrast Agent: A Series on Contrast Echocardiography, Article 2. Journal of the American Society of Echocardiography. 13(6). 629–636. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact